Vaccine against Mumps containing a Jeryl-Lynn virus strain
AssigneeSmithKline Beecham Biologicals s.a.
InventorsNigel Maurice Harford, Brigitte Desiree Alberte Colau, Jean Didelez
Life of this patent
Estimating the term…
Abstract
A new mumps vaccine is presented, comprising a homogeneous pure isolate derived from the Jeryl-Lynn strain of mumps virus.
Claims14
A mumps vaccine comprising a substantially homogeneous immunogenic Jeryl-Lynn isolate, the vaccine not contaminated with more than 10% of another Jeryl-Lynn isolate.
A combined vaccine comprising a substantially homogeneous immunogenic Jeryl-Lynn isolate and one or more viruses selected from the group consisting of an attenuated measles virus, an attenuated rubella virus, a killed measles virus, and a killed rubella virus.
A combined vaccine comprising a substantially homogeneous immunogenic Jeryl-Lynn isolate and a subunit of one or more viruses selected from the group consisting of:
- an attenuated measles virus, an attenuated rubella virus, a killed measles virus, and a killed rubella virus.
A method of producing a vaccine comprising a substantially homogeneous immunogenic Jeryl-Lynn isolate, the vaccine not contaminated with more than 10% of another Jeryl-Lynn isolate, the method comprising passaging a Jeryl Lynn preparation on a suitable cell line that supports the passage of a Jeryl-Lynn isolate;
- and
- selecting a pure culture using the steps of either:
- a. limit dilution;
- or
- b. individual plaque isolation.
Dependencies are inferred from the claim text.